Table 1. Anthropometric data at baseline and after rhGH therapy onset
Chronological age (bone age)Height (SDS)Growth velocity (SDS)DXA (baseline)DXA2DXA3DXA4
Patient 1
Baseline15.5 (12.0)125.5 (−5.9)Weight (kg)36.736.835.961.3
1st year16.5 (13.0)137.8 (−4.2)12.8 (+31.0)BMI (kg/m2)23.320.7520.9127.1
2nd year17.5 (14.0)143.8 (−3.1)6.0 (+21.0)BMD (g/cm2)0.64400.7330.7811,050
3rd year18.5 (14.0)146.4 (−2.6)2.6 (+14.4)BMD (Z‐score)−3.7−2.7−2.20.4
4th year19.5148.8 (−2.2)2.3 (+12.5)TBS1,2701,2801,400N.A.
Patient 2
Baseline8.1 (6.5)100.4 (−5.0)Weight (kg)17.518.520.250.4
1st year9.0 (7.5)114.0 (−3.2)14.2 (+11.4)BMI (kg/m2)17.415.7514.7620.81
2nd year10.0 (9.0)125.1 (−2.0)11.1 (+5.5)BMD (g/cm2)0.4780.5150.5230.825
3rd year11.1 (10.5)133.2 (−1.5)8.2 (+1.4)BMD (Z‐score)−1.3−0.7−1.0−1.0
4th year12.0 (11.3)138.5 (−1.6)5.7 (−1.2)TBS1,2601,2701,360N.A.
5th year13.0 (12.5)146.2 (−1.2)7.8 (+2.8)
6 year & 6 month14.5 (13.5)152.9 (−0.7)5.0 (+1.2)
Patient 3
Baseline6.0 (3.5)84.5 (−6.7)Weight (kg)9.811.512.736
1st year7.0 (5.0)98.5 (−4.4)14.6 (+9.3)BMI (kg/m2)13.715.7714.7618.90
2nd year8.0 (6.5)106.9 (−3.6)8.4 (+3.7)BMD (g/cm2)0.3970.4460.4700.678
3rd year9.0 (7.5)114.2 (−3.2)7.4 (+1.1)BMD (Z‐score)−2.2−1.4−1.0−1.1
4th year10.0 (8.8)119.3 (−2.9)5.4 (+0.5)TBS1,2601,2701,360N.A.
5th year10.9 (10.0)126.4 (−2.5)7.1 (+1.3)
6 year & 6 month12.3 (11.3)137.5 (−1.9)7.4 (+0.5)
  • SDS, standard deviation score. Bone mineral density (BMD) and trabecular bone structure (TBS) in DXA (dual‐energy absorptiometry analysis) in the three patients before (baseline) and after 6 months (DXA2), 1 year (DXA3), and 6.5 years (DXA4) of rhGH therapy onset (patient 1 received 4.5 years of treatment, and patients 2 and 3 remain on treatment). All of the DXA data refer to lumbar spine (L1–L4) (N.A., not available).